SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

BlossomHill Therapeutics, Inc. (BLSM) News

Track canonical SquawkNews coverage tagged to BLSM, BlossomHill Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 1 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol BLSM Asset equity Sector Markets 90 days 1 Last 16.355 Updated Aug 18, 2026, 11:00 AM UTC Open live news feed
H BlossomHill Therapeutics gets FDA Fast Track for BH-30643 in EGFR C797S+ NSCLC BlossomHill Therapeutics announces the FDA grants Fast Track designation to BH-30643, its macrocyclic OMNI-EGFR™ inhibitor, for treating advanced EGFR C797S-positive NSCLC. REGULATION | Aug 18, 2026, 11:00 AM UTC